Skip to main content
Premium Trial:

Request an Annual Quote

CytRx Licenses RNAi Technology from U Mass Medical School

NEW YORK, April 21 - CytRx has signed a license agreement with the University of Massachusetts Medical School for its proprietary portfolio of applications for RNAi-based gene silencing technology in obesity, type 2 diabetes, and cancer.


As part of the agreement, CytRx will issue UMMS approximately 1.6 million shares of its common stock, establishing the university as the company's second-largest shareholder.


CytRx said the suite of applications it is licensing from UMMS "may be considered the world's largest proprietary portfolio" of such technology. UMMS faculty member Craig Mello and Andrew Fire of the Carnegie Institution of Washington developed the approach, which uses RNA to selectively turn off the harmful genes of infectious viruses or malignant tumor cells, in 1997.


Louis Ignarro, chairman of CytRx's scientific advisory board, will head up the gene silencing research collaboration between CytRx and UMMS.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.